Related Experiment Video

Updated: May 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic

Joon Young Song1, Moon H Nahm, M Allen Moseley

  • 1Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. infection@korea.ac.kr

Journal of Korean Medical Science
|January 24, 2013
PubMed

Insights

Pneumococcal serotypes, not genetics, determine disease severity. Serotype 14 causes non-bacteremic pneumonia, while others like 1 and 19A cause invasive disease and complications. Serotype and genotype impact antibiotic resistance.

Area of Science:

  • Microbiology
  • Epidemiology
  • Vaccinology

Background:

  • Streptococcus pneumoniae asymptomatically colonizes the nasopharynx, with disease spectrum linked to capsular serotype.
  • Specific serotypes (1, 4, 5, 7F, 8, 12F, 14, 18C, 19A) are associated with invasive pneumococcal disease (IPD).
  • Serotype 14 is a common cause of non-bacteremic pneumonia in adults post-PCV7 introduction.

Purpose of the Study:

  • To review the clinical spectrum of Streptococcus pneumoniae infections.
  • To highlight the role of capsular serotypes and genotypes in disease presentation and antibiotic resistance.
  • To emphasize the importance of serosurveillance for vaccination strategies.

Main Methods:

  • Literature review of Streptococcus pneumoniae epidemiology and clinical manifestations.
  • Analysis of serotype-specific disease associations, including IPD, pneumonia, empyema, and meningitis.
  • Examination of genotype-host interactions concerning antibiotic resistance.

Main Results:

  • Serotypes 1 and 19A are linked to invasive pneumococcal pneumonia; serotype 14 to non-bacteremic pneumonia.
  • Serotypes 1, 3, and 19A are associated with empyema and hemolytic uremic syndrome.
  • Multidrug-resistant strains (e.g., serotype 19A CC320/271, 6C, 6D ST282) are globally prevalent and linked to specific genotypes.

Conclusions:

  • Capsular serotype dictates pneumococcal disease invasiveness and clinical outcomes.
  • Genotype is a stronger predictor of antibiotic resistance than serotype.
  • Geographic and temporal variations in pneumococcal epidemiology necessitate nationwide serosurveillance for effective vaccination strategies.
Keywords:
Bacterial CapsulesPneumococcal InfectionsPolysaccharides, BacterialSerotypingStreptococcus pneumoniae

More Related Videos

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/4306:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...